307 related articles for article (PubMed ID: 23103567)
1. Targeting FOXM1 in cancer.
Halasi M; Gartel AL
Biochem Pharmacol; 2013 Mar; 85(5):644-652. PubMed ID: 23103567
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
4. A new target for proteasome inhibitors: FoxM1.
Gartel AL
Expert Opin Investig Drugs; 2010 Feb; 19(2):235-42. PubMed ID: 20074015
[TBL] [Abstract][Full Text] [Related]
5. FoxM1 as a novel therapeutic target for cancer drug therapy.
Xu XS; Miao RC; Wan Y; Zhang LQ; Qu K; Liu C
Asian Pac J Cancer Prev; 2015; 16(1):23-9. PubMed ID: 25640357
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments.
Raghuwanshi S; Gartel AL
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189015. PubMed ID: 37913940
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.
Wang Z; Banerjee S; Kong D; Li Y; Sarkar FH
Cancer Res; 2007 Sep; 67(17):8293-300. PubMed ID: 17804744
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 inhibitors as potential anticancer drugs.
Gartel AL
Expert Opin Ther Targets; 2008 Jun; 12(6):663-5. PubMed ID: 18479213
[TBL] [Abstract][Full Text] [Related]
9. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.
Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V
Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210
[TBL] [Abstract][Full Text] [Related]
10. Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy.
Shi M; Cui J; Xie K
Curr Drug Targets; 2013 Sep; 14(10):1192-202. PubMed ID: 23834153
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 in Cancer: Interactions and Vulnerabilities.
Gartel AL
Cancer Res; 2017 Jun; 77(12):3135-3139. PubMed ID: 28584182
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Bao-Hongluan ; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Jun; 71(6):345-8. PubMed ID: 27455555
[TBL] [Abstract][Full Text] [Related]
13. Is there potential to target FOXM1 for 'undruggable' lung cancers?
Kalinichenko VV; Kalin TV
Expert Opin Ther Targets; 2015 Jul; 19(7):865-7. PubMed ID: 25936405
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box M1 transcription factor: a novel target for cancer therapy.
Wang Z; Ahmad A; Li Y; Banerjee S; Kong D; Sarkar FH
Cancer Treat Rev; 2010 Apr; 36(2):151-6. PubMed ID: 20022709
[TBL] [Abstract][Full Text] [Related]
15. Targeting FOXM1 auto-regulation in cancer.
Gartel AL
Cancer Biol Ther; 2015; 16(2):185-6. PubMed ID: 25603426
[No Abstract] [Full Text] [Related]
16. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
17. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
[TBL] [Abstract][Full Text] [Related]
18. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
Ahmad A; Wang Z; Kong D; Ali S; Li Y; Banerjee S; Ali R; Sarkar FH
Breast Cancer Res Treat; 2010 Jul; 122(2):337-46. PubMed ID: 19813088
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
20. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA.
Wang M; Gartel AL
Oncotarget; 2011 Dec; 2(12):1218-26. PubMed ID: 22203467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
